Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2371-2387

  VanderWel, Scott N ^a   Harvey, Patricia J ^a   McNamara, Dennis J ^a   Repine, Joseph T ^a   Keller, Paul R ^a   Quin III, John ^a   Booth, R John ^a   Elliott, William L ^a   Dobrusin, Ellen M ^a   Fry, David W ^a   Toogood, Peter L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (4 PIPERAZIN 1 YLPHENYLAMINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; 8 CYCLOPENTYL 5 METHYL 7 OXO 2 (4 PIPERAZIN 1 YLPHENYLAMINO) 7,8 DIHYDROPYRIDO[2,3 D]PYRIMIDINE 6 CARBOXYLIC ACID METHYL ESTER; ADENOSINE TRIPHOSPHATE; BUTYROLACTONE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; OLOMOUCINE; PURVALANOL A; PYRIDO[2,3 D]PYRIMIDIN 7 ONE DERIVATIVE; PYRIMIDINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CHEMICAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; PROTO-ONCOGENE PROTEINS; PYRIDINES; PYRIMIDINES; STEREOISOMERISM; TRANSPLANTATION, HETEROLOGOUS;

EID: 20244366405     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049355+     Document Type: Article

References (87)

1. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
2. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1, 222-231.
3. Sherr, C. J. Cancer Cell Cycles. Science 1996, 274, 1672-1677.
4. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 1997, 13, 261-291.
5. Sherr, C. J.; Roberts, J. M. CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression. Genes Dev. 1999, 13, 1501-1512.
6. Fry, D. W.; Garrett, M. D. Inhibitors of Cyclin-Dependent Kinases as Therapeutic Agents for the Treatment of Cancer. Curr. Opin. Oncologic, Endocrine Metab. Invest. Drugs. 2000, 2, 40-59.
7. Garrett, M. D.; Fattaey, A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 1999, 9, 104-111.
8. Fisher, P. M.; Gianella-Borradori, A. CDK Inhibitors in Clinical Development for the Treatment of Cancer. Expert. Opin. Investig. Drugs 2003, 12, 955-970.
9. Huwe, A.; Mazitschek, R.; Giannis, A. Small Molecules as Inhibitors of Cyclin-Dependent Kinases. Angew. Chem. Int. Ed. 2003, 42, 2122-2138.
10. Fisher, P. M. Recent Advances and New Directions in the Discovery and Development of Cyclin-Dependent Kinase Inhibitors. Curr. Opin. Drug Discuss. Dev. 2001, 4, 623-634.
11. Rosania, G. R.; Chang, Y.-T. Targeting Hyperproliferative Disorders with Cyclin Dependent Kinase Inhibitors. Exp. Opin. Ther. Pat. 2000, 10, 215-230.
12. Webster, K. R.; Kimball, S. D. Novel Drugs Targeting the Cell Cycle. Emerging Drugs 2000, 5, 45-59.
13. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. J. Med. Chem. 2000, 43, 1-18.
14. Mani, S.; Wang, C.; Wu, K.; Francis, R.; Pestell, R. Cyclin-Dependent Kinase Inhibitors; Novel Anticancer Agents. Exp. Opin. Invest. Drugs 2000, 9, 1849-1870.
15. Meijer, L. Roscovitine and other purines as kinase inhibitors. From starfish Oocytes to Clinical trials. Acc. Chem. Res, 2003, 36, 417-425.
16. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N, J.; Endicott, J, A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
17. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S.-H. Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
18. Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, P.; Ludwig, O.; Grierson, D. S.; Leost, M.; Meijer, L.; Endicott, J. Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2-Inhibitor Complex. J. Med. Chem. 2000, 43, 1282-1292.
19. Wang, S.; McClue, S. J.; Ferguson, J. R.; Hull, J. D.; Stokes, S.; Parsons, S.; Westwood, R.; Fischer, P. M. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry 2001, 12, 2891-2894.
20. Chang, Y.-T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
21. Imbach, P.; Capraro, H.-G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-Trisubstituted Purines: Optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 91-96.
22. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors. Science 1998, 281, 533-538.
23. Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Shiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and Activity of 2,6,9-Trisubstituted Purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
24. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiffman, D. CVT-313, A Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation. J. Biol. Chem. 1997, 272, 29207-29211.
25. Havlíček, L.; Hanuš, J.; Veselý, J.; Leclerc, S.; Meijer, L.; Shaw, G.; Strnad, M. Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds. J. Med. Chem. 1997, 40, 408-412.
26. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J.-G.; Moulinoux, J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhihibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
27. Veselý, J.; Havlíček, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.-Y.; Detivaud, L.; LeClerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
28. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, J. K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In Vitro and IN Vivo Antitumor Properties of the Cyclin Dependent Kinase Inhibitor CYC202 (R-Roscovitine). Int. J. Cancer 2002, 102, 463-468.
29. Zaharevitz, D. W.; Gussio, R.; Leost, M.; Senderowicz, A. M.; Lahusen, T.; Kunick, C.; Meijer, L.; Sausville, E. A. Discovery and Initial Characterization of the Paullones, a Novel Class of Small-Molecule Inhibitors of Cyclin-dependent Kinases. Cancer Res. 1999, 59, 2566-2569.
30. Gussio, R.; Zaharevitz, D. W.; McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.; Meijer, L.; Sausville, E. A. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anti-Cancer Drug Des. 2000, 15, 53-66.
31. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted Paullones: CDK1/Cyclin B-Inhibiting Property and In Vitro Antiproliferative Activity. Bioorg. Med. Chem. Lett. 2000, 10, 567-569.
32. Schultz, C.; Link, A.; Loest, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, A Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity. J. Med. Chem. 1999, 42, 2909-2919.
33. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Loest, M.; Meijer, L. 2-Substituted Paullones: CDK1/Cyclin B-Inhibiting Property and In Vitro Antiproliferative Activity. Bioorg. Med. Chem. Lett. 2000, 10, 567-569.
34. Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M., Parsons, R. J., Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-Based Design of 2-Arylamino-4- cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
35. Anderson, M.; Beattie, J. F.; Breault, G. A.; Breed, J.; Byth, K. F.; Culshaw, J. D.; Ellston, R. P. A.; Green, S.; Minshull, C. A.; Norman, R. A.; Pauptit, R. A.; Stanway, J.; Thomas, A. P.; Jewsbury, P. J. Imidazo[1,2-α] pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Indentified Through Structure-Based Hybridisation. Bioorg. Med. Chem. Lett. 2003, 13, 3021-3026.
36. Tang, J.; Shewchuk, L. M.; Sato, H.; Hasegawa, M.; Washio, Y.; Nishigaki, N. Anilinopyrazole as Selective CDK2 Inhibitors: Design, Synthesis, Biological Evaluation, and X-ray Crystallographic Analysis. Bioorg. Med. Chem. Lett. 2003, 13, 2985-2988.
37. Misra, R. N.; Xiao, H.; Rawlins, D. B.; Shan, W.; Kellar, K. A.; Mulheron, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball, S. D.; Webster, K. R. LH-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases: Highly Potent 2,6-Difluorophenacyl Analogues. Bioorg. Med. Chem. Lett. 2003, 13, 2405-2408.
38. Misra, R. N.; Rawlins, D. B.; Xiao, H.; Shan, W.; Bursuker, I.; Kellar, K. A.; Mulheron, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball, S. D.; Webster, K. R. 1H-Pyrazolo[3,4-o]pyridine Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 2003, 13, 1133-1136.
39. Mesguiche, V.; Parsons, R. J.; Arris, C. E.; Bentley, J.; Boyle, F. T.; Curtin, N. J.; Davies, T. G.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Newell, D. R.; Noble, M. E. M.; Wang, L. Z.; Hardcastle, I. R. 4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 217-222.
40. Song, Y.; Wang, J.; Teng, S. F.; Kesuma, D.; Deng, Y.; Duan, J.; Wang, J. H.; Qi, R. Z.; Sim, M. M. β-Carbolines as Specific Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 2002, 12, 1129-1132.
41. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H.-Y.; Lu, S.; Qian, L.; Han, W.-C.; Shan, W.; Mitt, T.; Cai, Z.-W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. J. Med. Chem. 2002, 45, 3905-3927.
42. Ortega, M. A.; Montoya, M. E.; Zarranz, B.; Jaso, A.; Aldana, I.; Leclerc, S.; Meijer, L.; Monge, A. Pyrazolo[3,4-b]quinoxalines. A New Class of Cyclin-Dependent Kinases Inhibitors. Bioorg. Med. Chem. Lett. 2002, 10, 2177-2184.
43. Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J.-M. Structure-Based Design and Protein X-ray Analysis of a Protein Kinase Inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 221-224.
44. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. Science 2001, 291, 134-137.
45. Sielecki, T. M.; Johnson, T. L.; Liu, J.; Muckelbauer, J. K.; Grafstrom, R. H.; Cox, S.; Boylan, J.; Burton, C. R.; Chen, H.; Smallwood, A.; Chang, C.-H.; Boisclair, M.; Benfield, P. A.; Trainor, G. L.; Seitz, S. P. Quinazolines as Cyclin Dependent Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
46. Furet, P.; Meyer, T.; Mittl, P.; Fretz, H. Identification of cyclin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. J. Comput.-Aided Mol. Des. 2001, 15, 489-495.
47. Sasaki, S.; Hashimoto, T.; Obana, N.; Yasuda, H.; Uehara, Y.; Maeda, M. Design of New Inhibitors for CDC2 Kinase Based on a Multiple Pseudosubstrate Structure. Bioorg. Med. Chem. Lett. 1988, 8, 1019-1022.
48. Seong, Y.-S.; Min, C.; Li, L.; Yang, J. Y.; Kim, S.-Y.; C. X.; Kim, K.; Yuspa, S. H.; Chung, H.-H.; Lee, K. S. Characterization of a Novel Cyclin-Dependent Kinase 1 Inhibitor, BMI-1026. Cancer Res. 2003, 63, 7384-7391.
49. Murthi, K. K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M. D.; Worland, P. J.; Mansuri, M. M.; Pal, K. Structure-Activity Relationship Studies of Flavopiridol Analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-1041.
50. Li, X.; Huang, P.; Cui, J. J.; Zhang, J.; Tang, C. Novel Pyrrolyllactone and Pyrrolyllactam Indolinones as Potent Cyclin-Dependent Kinase 2 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1939-1942.
51. Liu, J.-J.; Dermatakis, A.; Lukacs, C.; Konzelmann, F.; Chen, Y.; Kammlott, U.; Depinto, W.; Yang, H.; Yin, X.; Chen, Y.; Schutt, A.; Simcox, M. E.; Luk, K.-C. 3,5,6-Trisubstituted Naphthostyrils as CDK2 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 2465-2468.
52. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. J. Med. Chem. 2001, 44, 4339-4358.
53. Yue, E. W.; Higley, C. A.; DiMeo, S. V.; Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton, C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C.-H.; Seitz, S. P.; Trainor, G. L. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3.Structure Activity Relationships at C3. J. Med. Chem. 2002, 45, 5233-5248.
54. Nugiel, D. A.; Vidwans, A.; Etzkorn, A.-M.; Rossi, K. A.; Benfield, P. A.; Burton, C. R.; Cox, S.; Doleniak, D.; Seitz, S. P. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern. J. Med. Chem. 2002, 45, 5224-5232.
55. Nugiel, D. A.; Etzkorn, A.-M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. P. Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors. J. Med. Chem. 2001, 44, 1334-1336.
56. Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A Novel cdk2-selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells. Cancer Res. 2001, 61, 6170-6177.
57. Andreani, A.; Cavalli, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Recanatini, M.; Gamier, M.; Meijer, L. Imidazo[2,1-b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK/cyclin B inhibition. Anti-Cancer Drug Des. 2000, 15, 447-452.
58. Honma, T.; Hayaski, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, L; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 2001, 44, 4615-4627.
59. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Moroshima, H. A Novel Approach for the Development of Selective Cdk4 Inhibitors: Library Design Based on Locations of Cdk4 Specific Amino Acid residues. J. Med. Chem. 2001, 44, 4628-4640.
60. Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Fabbro, D.; Chaudhuri, B. Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4. J. Natl. Cancer Inst. 2001, 93, 436-446.
61. Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 1: Identification and Optimisation of Substituted 4,6-Bis Anilino Pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960.
62. Breault, G. A.; Ellston, R. P. A.; Green, S.; James, S. R.; Jewsbury, P. J.; Midgley, C. J.; Pauptit, R. A.; C. A.; Minshull, Tucker, J. A.; Pease, J. E. Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 2: Identification as Optimisation of Substituted 2,4-Bis Anilino Pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2961-2966.
63. Sanchez-Martinez, C.; Shih, C.; Faul, M. M.; Zhu, G.; Paal, M.; Somoza, C.; Li, T.; Kumrich, C. A.; Winneroski, L. L.; Xun, Z.; Brooks, H. B.; Patel, B. K. R.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Considine, E.; Dempsey, J. A.; Ogg, C. A.; Campbell, R. M.; Anderson, B. A.; Wagner, J. Aryl-[α]pyrrolo[3,4,-c]carbazoles as Selective Cyclin D1-CDK4 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3835-3839.
64. Sanchez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H. B.; Patel, B. K. R.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Ogg, C. A.; Considine, E.; Dempsey, J. A.; Zhang, F. Studies on Cyclin-Dependent Kinase Inhibitors: Indolo-[2,3-α]pyrrolo[3,4-c]carbazoles versus Bis-indolylmaleimides. Bioorg. Med. Chem. Lett. 2003, 13, 3841-3846.
65. Engler, T. A.; Furness, K.; Malhotra, S.; Sanchez-Martinez, C.; Shih, C.; Xie, W.; Zhu, G.; Zhou, X.; Conner, S.; Faul, M. M.; Sullivan, K. A.; Kolis, S. P.; Brooks, H. B.; Patel, B.; Schultz, R. M.; DeHahn, T. B.; Kirmani, K.; Spencer, C. D.; Watkins, S. A.; Considine, E. L.; Dempsey, J. A.; Ogg, C. A.; Stamm, N. B.; Anderson, B. D.; Campbell, R. M.; Vasudevan, V.; Lytle, M. L. Novel, Potent and Selective Cyclin D1/CDK4 Inhibitors: Indolo-[6,7-α] pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett. 2003, 13, 2261-2267.
66. Zhu, G.; Conner, S.; Zhou, X.; Shih, C.; Brooks, H. B.; Considine, E.; Dempsey, J. A.; Ogg, C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis of Quinolinyl/Isoquinolinyl[α]pyrrolo[3,4-c] Carbazoles as Cyclin D1/CDK4 Inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1231-1235.
67. Zhu, G.; Conner, S. E.; Zhou, X.; Shih, C.; Li, T.; Anderson, B. D.; Brooks, H. B.; Campbell, R. M.; Considine, E.; Dempsey, J. A.; Faul, M. M.; Ogg, C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis, Structure-Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors. J. Med. Chem. 2003, 46, 2027-2030.
68. Carini, D. J.; Kaltenbach, R. F., III; Liu, J.; Benfield, P. A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C. R.; Cox, S.; Grafstrom, R.; Harrison, B. A.; Harrison, K.; Akamike, E.; Markwalder, J. A.; Nakano, Y.; Seitz, S. P.; Sharp, D. M.; Trainor, G. L.; Sielecki, T. M. Identification of Selective Inhibitors of Cyclin Dependent Kinase 4. Bioorg. Med. Chem. Lett. 2001, 11, 2209-2211.
69. Ryu, C.-K.; Kang, H.-Y.; Lee, S. K.; Nam, K. A.; Hong, C. Y.; Ko, W.-G.; Lee, B.-H. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as Inhibitors of Cyclin-Dependent Kinase 4 and Cytotoxic Agents. Bioorg. Med. Chem. Lett. 2000, 10, 461-464.
70. Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product. Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
71. Jeong, H.-W.; Kim, M.-R.; Son, K.-H.; Han, M. Y.; Ha, J.-H.; Garnier, M.; Meijer, L.; Kwon, B.-M. Cinnamaldehydes Inhibit Cyclin Dependent Kinase 4/Cyclin D1. Bioorg. Med. Chem. Lett. 2000, 10, 1819-1822.
72. Murthi, K. K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M. D.; Worland, P. J.; Mansuri, M. M.; Pal, K. Structure-Activity Relationship Studies of Flavopiridol Analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-1041.
73. Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and Oxoflavopiridols, Cyclin-Dependeht Kinase 1-Selective Inhibitors: Synthesis and Biological Effects. J. Med Chem. 2000, 43, 4126-4134.
74. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Loest, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60-67.
75. Meijer, L.; Thunnissen, A.-M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L.-H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y.-Z.; Biernat, J.; Mandelkow, E.-M.; Kim, S.-H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
76. DePinto, W. E.; Yin, X.; Smith, M.; Kolinsky, K.; Desai, B.; Rowan, K.; Wang, K.; Perrotta, A.; Gillespie, P. The In Vitro and In Vivo Effects of Small Molecule Inhibitors of Cyclin Dependent Kinase 4. Presented at the American Association of Cancer Research 95th Annual National Meeting, Mar 27-31, 2003, Orlando, FL, Abstract #3126.
77. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido-[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
78. Fry, D. W.; Bedford, D. C.; Harvey, P. H.; Fritsch, A.; Keller, P. R.; Wu, Z.; Dobrusin, E.; Leopold, W. R.; Fattaey, A.; Garrett, M. D. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 2001, 276, 16617-16623.
79. Toogood, P. L. Cyclin-Dependent Kinase Inhibitors for Treating Cancer. Med. Res. Rev. 2001, 21, 487-498.
80. Gray, N.; Détivaud, L.; Doerig, C.; Meijer, K. ATP-Site Directed Inhibitors of cyclin-Dependent Kinases. Curr. Med. Chem. 1999, 6, 859-875.
81. Griffith, W. P.; Ley, S. V.; Whitcombe, G. P.; White, A. D. J. Chem. Soc., Chem. Commun. 1987, 1625.
82. 3). A trifluoromethide equivalent. J. Am. Chem. Soc. 1989, 111, 393-395.
83. Walter, M. W.; Adlington, R. M.; Baldwin, J. E.; Schofield, C. J. Reaction of (Trifluoromethyl)trimethylsilane with Oxazolidin-5-ones: Synthesis of Peptidic and Nonpeptidic Trifluoromethyl Ketones J. Org. Chem. 1998, 63, 5179-5192.
84. Dess, D. B.; Martin, J. C. Readily Accessible 12-I-5 Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones. J. Org. Chem. 1983, 48, 4155-4156.
85. Davis, F. A.; Stringer, O. D. Chemistry of Oxaziridines. 2. Improved Synthesis of 2-Sulfonyloxaziridines. J. Org. Chem. 1982, 47, 1774-1775.
86. Davis, F. A.; Jenkins, R. H., Jr; Awad, S. B.; Stringer, O. D.; Watson, W. H.; Galloy, J. Chemistry of Oxaziridines. 3. Asymmetric Oxidation of Organosulfur Compounds Using Chiral 2-Sulfonyloxaziridines. J. Am. Chem. Soc. 1982,104, 5412-5418.
87. Toodgood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6. J. Med. Chem. 2005, 48, 2388-2406.